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Colorectal malignancies demonstrating microsatellite
instability (MSI) have a very heterogeneous histological
appearance, better prognosis, and altered response to
therapy. Consequently, identification of the MSI pheno-
type is both relevant and interesting as a screening and
prognostic tool and as a potential predictive factor of
chemotherapeutic response. Several groups have ar-
gued for the exclusive use of mononucleotide markers
for MSI analysis. In this study, an alternative MSI typing
multiplex system of mononucleotide microsatellite re-
peats was developed. This system obviates the need to
compare allelic profiles between tumor and matching
normal DNA, rendering MSI analysis amenable to high
throughput. The quasi-monomorphic allelic distribu-
tion of five alternative mononucleotide markers was
evaluated in genomic DNA. Only SEC63 and CAT25 were
found to be quasi-monomorphic and were thus com-
bined with BAT25 and BAT26 from the Bethesda panel.
Consequently, 177 colorectal cancer samples previ-
ously analyzed by the Bethesda panel were tested for
MSI using this alternative mononucleotide panel. In an
attempt to resolve discordant cases, immunohisto-
chemistry of MLH1, MSH2, and MSH6 was performed.
The concordance between both panels reached 99.4%
when microsatellite stability and MSI-L were grouped
together. These new markers were subsequently multi-
plexed in a single polymerase chain reaction assay. The
resultingmononucleotide fluorescentmultiplexMSI assay
hashighaccuracy, reliability, and throughput, thus reduc-
ing the timeandcost involved inMSI testing. (J Mol Diagn
2008, 10:154–159; DOI: 10.2353/jmoldx.2008.070087)
High-frequency microsatellite instability (MSI-H) is a ge-
netic instability observed in virtually all tumors from pa-
tients with hereditary nonpolyposis colorectal cancer and
in a subset of sporadic colorectal cancers (CRCs). Its
hallmark is extensive instability in simple tandem repeat
nucleotide sequences (microsatellites) caused by a de-
fective DNA mismatch repair function.
Colorectal malignancies demonstrating MSI have a
very heterogeneous histological appearance, improved
prognosis, and altered response to chemotherapy and
radiotherapy.1,2 Consequently, identification of the MSI
phenotype can both be relevant and interesting as a
screening tool for hereditary nonpolyposis colorectal
cancer,3 as a prognostic marker, and as a potential pre-
dictive factor of chemotherapy response.4,5
MSI is defined as alterations in lengths of microsatel-
lites due to deletions or insertions of repeating units to
produce novel length alleles in tumor DNA when com-
pared with normal DNA from the same individual.6 The
absence of consensus markers for MSI analysis for
several years resulted in conflicting data. Presently, the
diagnosis of MSI in CRC is based on a set of five micro-
satellite markers (two mononucleotide and three dinucle-
otide repeats) proposed by the National Cancer Institute
Research Workshop in Bethesda.7 However, it has been
argued during a second consensus workshop held at the
end of 2002 that the original microsatellite panel has
limitations resulting from the inclusion of dinucleotide
markers, which are less sensitive and specific for detec-
tion of tumors with mismatch repair deficiencies. Among
the suggested changes was the exclusive use of mono-
nucleotide repeats improving the sensitivity of MSI de-
tection in CRC.8 An additional argument to use mono-
nucleotide markers is that they are more commonly
quasi-monomorphic, potentially obviating the need to
test the corresponding normal DNA.6
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Several groups have studied the use of mononucle-
otide loci to identify MSI in CRC tumors9–12 and very
recently a mononucleotide pentaplex MSI analysis sys-
tem kit is commercially available from Promega Corp.
(Madison, WI).6 In this study we developed an alternative
easy, in particular a cost-effective and simplified MSI
typing system of mononucleotide microsatellite repeats
requiring only a single polymerase chain reaction (PCR)
and obviating the need to compare allelic profiles be-
tween tumor and matching germline DNA rendering MSI
analysis amenable to high throughput.
BAT26 and BAT25 are the best known quasi-mono-
morphic mononucleotide repeats and have been proven
very useful for the identification of MSI even without the
use of corresponding germline DNA. Second, these
markers appear to undergo significant deletions in the
large majority of tumors with MSI.13,14 Nevertheless, to
establish an MSI analysis system with a similar or even
higher sensitivity than the Bethesda panel, the inclusion
of additional mononucleotide markers is recommended.8
Woerner et al15 identified a new set of genes frequently
affected by mutations in MSI-positive tumor cells. Four of
these mononucleotide repeats (PTHL3, SEC63, HPDMPK,
andU79260) showedmutation rates in 80%ormore ofMSI-H
CRCs and were suggested as new candidate genes for
diagnostic purposes. Similarly, Findeisen et al16 described
a novel T25 mononucleotide marker in the 3 untranslated
region of the CASP2 gene (CAT25) that displayed a quasi-
monomorphic repeat pattern in normal tissue and repre-
sented a highly promising candidate marker for future high-
throughput MSI testing.
These five alternative mononucleotide markers were
tested for monomorphic or quasi-monomorphic allele dis-
tribution, and their sensitivity in detecting MSI tumors was
studied. The most suitable markers were multiplexed with
BAT26 and BAT25, according to the step-by-step proto-
col of Henegariu et al,17 to establish an alternative, sim-
ple and sensitive MSI analysis system of mononucleotide
microsatellite repeats.
Materials and Methods
Sample Preparation and DNA Extraction
Genomic DNA was obtained from peripheral blood lym-
phocytes of 66 healthy Caucasian individuals at the Uni-
versity of Antwerp. Normal and tumor DNA were obtained
separately from formalin-fixed, paraffin-embedded tissue
blocks of 95 cervical cancers at the University of Gdansk,
Poland. Tumor DNA was obtained from 177 colorectal
cancer specimens at the University Hospital Antwerp, the
St. Augustinus Hospital, and the Ghent University Hospi-
tal. After manual microdissection, DNA was isolated as
described previously.18
Evaluation Monomorphic State
The quasi-monomorphic allele distribution of PTHL3,
SEC63, HPDMPK, U79260, and CAT25 was evaluated in
the genomic DNA of the peripheral white blood cells of
the 66 healthy control individuals mentioned above. Ad-
ditionally, normal DNA of 95 cervical carcinoma samples
was analyzed to verify the quasi-monomorphic allele dis-
tribution of these markers. Polymorphism was scored if
smaller or larger size amplimers were detected after cal-
culating the ratios of the peak areas of wild-type and
novel alleles in normal tissues. A twofold difference was
defined as threshold for allelic shifts.15
Bethesda Panel Assay
From an ongoing retrospective study on MSI in sporadic
CRC, 177 formalin-fixed, paraffin-embedded colorectal
cancer specimens were selected. These specimens
were typed for MSI using the standard Bethesda marker
panel as described previously.18 Fluorescent PCR prod-
ucts were analyzed by capillary electrophoresis using an
ABI 3100 Genetic Analyzer (Applied Biosystems, Lennik,
Belgium) and Genemapper software 3.7. For interpreta-
tion purposes, MSI at two or more loci was defined as
MSI-H, instability at a single locus was defined as MSI-L,
and no instability at any of the loci was defined as mic-
rosatellite stability (MSS).
Mononucleotide Marker Assay
The MSI analysis system consists of nearly monomorphic
mononucleotide markers. PCR primers for the amplifica-
tion of these markers were described elsewhere.15,16 The
sense primers were chemically labeled at the 5 end with
5-carboxyfluorescein fluorescent dyes. PCR was per-
formed in a total volume of 25 l using a final concentra-
tion of 200 mol/L deoxyribonucleotide triphosphates
(MBI Fermentas, St. Leon-Rot, Germany), 500 nmol/L
each sense and antisense primer (Eurogentec, Seraing,
Belgium), 1X PCR buffer (60 mmol/L Tris-SO4, pH 8.9; 18
mmol/L (NH4)SO4; 2 mmol/L MgSO4) and 1 unit of Dis-
coverase denaturing high performance liquid chromatog-
raphy DNA polymerase (Invitrogen, Merelbeke, Belgium).
Again, as described for the Bethesda panel assay, fluo-
rescent PCR products were analyzed by capillary elec-
trophoresis using an ABI 3100 Genetic Analyzer (Applied
Biosystems) and Genemapper software 3.7.
Immunohistochemistry
Discordant cases were examined by immunohistochem-
istry for MLH1, MSH2, and MSH6. Sections, 4 m thick,
were prepared from formalin-fixed paraffin-embedded
tissue for immunohistochemistry. Sections were deparaf-
finized, dehydrated, and subjected to heat antigen re-
trieval by microwave in EDTA buffer for 10 minutes at 600
W and for 10 minutes at 300 W for MLH1 detection.
Antigen retrieval for MSH2 and MSH6 was performed by
EDTA buffer in a heating bath for 15 minutes at 100°C.
Endogenous peroxidase activity was quenched by incu-
bating the slides in peroxidase block EnVision (DAKO
EnVision kit, DakoCytomation, Copenhagen, Denmark).
Incubations with primary monoclonal antibodies were
performed as follows: anti-MLH1 (clone G168–15, diluted
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1:100, BD Biosciences PharMingen, San Diego, CA); anti-
MSH2 (clone FE11, diluted 1:250, Oncogene Research
Products, San Diego, CA); and anti-MSH6 (clone 44, diluted
1:250, BD Biosciences PharMingen), all for 1 hour at room
temperature. After incubation, the slides were washed, and
anti-mouse secondary antibodies conjugated to peroxi-
dase-labeled polymer (DAKO) were applied for 30 minutes.
The peroxidase activity was developed by incubation with
3,3-diaminobenzidine chromogen solution (DAKO) for 10
minutes. The sections were then counterstained with hema-
toxylin. Loss of protein expression was scored as absence
of nuclear staining in tumor cells despite nuclear staining in
proliferating cells in normal crypts and stroma.
Multiplex PCR Assay
The two most sensitive quasi-monomorphic mononucle-
otide markers were combined with Bat26 and Bat25 in a
multiplex assay. Again, all sense primers were chemically
labeled at the 5 end with 5-carboxyfluorescein, with the
exception of Bat26 primer, which was labeled with hexa-
chlorofluorescein. To perform four PCR reactions in one
tube, the step-by-step protocol of Henegariu et al17 was
used. First, a PCR program was designed to amplify all
loci individually under the same conditions. Then, these
primers were combined in various mixtures to amplify all
loci simultaneously. This required alterations and optimi-
zation of several parameters of the reaction. Primer,
buffer and MgSO4 concentrations were all optimized to
perform a multiplex reaction of the four markers. PCR was
performed in a total volume of 25 l using a final concen-
tration of 200 mol/L deoxyribonucleotide triphosphates
(MBI Fermentas), 0.8X PCR buffer (48 mmol/L Tris-SO4
pH 8.9, 14.4 mmol/L (NH4)SO4, and 1.6 mmol/L MgSO4),
3.5 mmol/L MgSO4, 1 unit of Discoverase denaturing high
performance liquid chromatography DNA polymerase
(Invitrogen) and 500 nmol/L BAT25 and CAT25 sense
and antisense primer, 600 nmol/L BAT26 sense and an-
tisense primer, and 80 nmol/L SEC63 sense and anti-
sense primer (Eurogentec). The multiplex assay was ver-
ified in all 177 CRC and in 10 cervical carcinoma samples
previously analyzed by the Bethesda panel and the
mononucleotide markers. Although only four markers
were analyzed, MSI at two or more loci was defined as
MSI-H, instability at a single locus was defined as MSI-L,
and no instability at any of the loci was defined as MSS.
Statistical Analysis
To quantify the degree of agreement between the Be-
thesda panel and the new mononucleotide panel, the
kappa statistical test was used.
Results
Monomorphic State
The monomorphic or quasi-monomorphic allele distribu-
tion of PTHL3, SEC63, HPDMPK, U79260, and CAT25
was evaluated in genomic DNA of peripheral white blood
cells of the 66 control individuals and in normal DNA of
the 95 cervical carcinoma samples. U79260 did not pro-
vide reproducible results in the peripheral blood sam-
ples. HPDMKP and PTHL3 were polymorphic in 42.9%
and 29.4%, respectively, whereas SEC63 and CAT25
showed monomorphism in 100% and 98.8% of all sam-
ples examined, respectively. Therefore, CAT25 and
SEC63 were selected to be combined with BAT25 and
BAT26 from the Bethesda panel to form a new quasi-
monomorphic mononucleotide marker panel.
MSI Analysis Using Bethesda Panel
All samples could be typed for MSI using the Bethesda
panel. Thirty of the 177 colorectal tumors, selected from a
larger ongoing retrospective study, showed MSI-H, while
four of 177 showed MSI-L and 143 of 177 MSS (data not
shown). For all but one of the MSI-H samples, the Be-
thesda panel showed instability at both mononucleotide
markers (BAT26 and BAT25).
MSI Analysis Using Mononucleotide Markers
All samples could be typed for MSI using the quasi-
monomorphic mononucleotide markers selected. In the
177 cases of CRC there was a good overall concordance
between both assays, since 29 of 30 MSI-H tumors iden-
tified by the Bethesda panel were also recognized as
MSI-H by this new panel (Table 1). The one MSI-H sam-
ple missed by the quasi-monomorphic mononucleotide
panel showed instability in only two dinucleotide markers
of the Bethesda panel. Of the four cases identified as
MSI-L by the Bethesda assay, all were classified as MSS
using the new mononucleotide panel (Table 1). These
samples only showed instability in one dinucleotide
marker of the Bethesda panel. To resolve the discordant
cases, immunohistochemistry was performed for MLH1,
MSH2, and MSH6 on the one discordant MSI-H case and
two of four cases identified as MSI-L by the Bethesda
assay. The discordant MSI-H case seemed to have lost
expression of the MSH2 protein, while one MSI-L showed
loss of expression of MSH6 (data not shown). The second
MSI-L case showed no loss of expression of mismatch
repair genes (data not shown). Regrettably, from the
remaining MSI-L cases insufficient material was available
to perform immunohistochemistry.
Additionally, the sensitivity and specificity of the mono-
nucleotide markers and the Bethesda panel for MSI anal-
ysis was calculated. MSI analysis using all seven markers
was used as a gold standard, and MSI-H was scored
Table 1. Comparison of MSI Analysis by Bethesda Panel
and Quasi-Monomorphic Mononucleotide Panel
Mononucleotide panel
Bethesda panel
MSI-H MSI-L MSS
MSI-H 29 0 0
MSI-L 0 0 0
MSS 1 4 143
Kappa: 0.905 (95CI: 0.8230.987).
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when at least three of seven (40%) samples were in-
stable and MSI-L/MSS were grouped together. All mono-
nucleotide markers showed a specificity of 100%. BAT25,
BAT26, and CAT25 showed a sensitivity of 100%, while
SEC63 showed a sensitivity of 56.7%. For the Bethesda
panel, D2S123 had a sensitivity of 53.6% and a specific-
ity of 97.3%, while D5S346 and D17S250 both showed a
specificity of 99.3% but a sensitivity of only 25% and
34.5%, respectively, indicating a superiority of mononu-
cleotide over dinucleotide repeats in detecting MSI.
The overall concordance between the quasi-monomor-
phic mononucleotide MSI analysis assay and the Be-
thesda assay was 97.1%: kappa, 0.905 (95CI,
0.8230.987) (Table 1). If MSS and MSI-L tumors were
grouped together the agreement reached 99.4%: kappa,
0.980 (95CI, 0.940–1.019) (Table 2).
The four quasi-monomorphic mononucleotide markers
were combined in a single multiplex assay as described
by the step-by-step protocol of Henegariu et al.10 All CRC
and 10 cervical carcinomas were used for evaluation of
the multiplex PCR. All samples could be typed for MSI
using the quasi-monomorphic mononucleotide multiplex
PCR assay. All (100%) of the MSI-H CRC tumors identi-
fied by the Bethesda and the mononucleotide panel were
recognized by the multiplex assay. None of the MSS
colorectal tumors showed instability in any mononucle-
otide marker of the multiplex assay and were therefore
scored correctly. Additionally, the cervical carcinoma
samples were also scored correctly using the multiplex
assay. Examples of MSI-H and MSS profiles generated
with the quasi-monomorphic mononucleotide multiplex
PCR assay are shown in Figure 1.
Discussion
The current standard method of MSI analysis is relatively
time-consuming, laborious, and expensive, due to the
need to compare allelic profiles between tumor and
matching germline DNA. Fluorescent multiplex PCR of
mononucleotide repeats and the computerized fragment
analysis method, as described here and by others6,9–11
was designed to render MSI typing feasible for high-
throughput application. This type of assay allows screen-
ing of large sample numbers with high specificity and
sensitivity and clear interpretation of the data.
The ideal markers for MSI typing should match the
following criteria: 1) a quasi-monomorphic allele pattern
in all human populations, 2) 100% mutation frequency in
MSI-H tumors, and 3) no mutations in MSS tissue speci-
mens.16 BAT26 and BAT25 mononucleotide markers
have already proved to be very useful for the identifica-
tion of MSI due to the quasi-monomorphic nature in Cau-
casian populations of both loci and the sensitivity of both
markers to MSI.13,14,19,20 Although adequate in the great
majority of circumstances, analysis of additional repeats
may be needed in some cases, especially in individuals
of African origin.21,22
Five additional mononucleotide markers (PTHL3,
SEC63, HPDMPK, U79260, and CAT25) were selected
after in-depth review of the literature.15,16 Two of these
selected markers (SEC63 and CAT25) were identified as
quasi-monomorphic and, similar to BAT26 and BAT25,
highly sensitive to somatic deletions in MSI-H tumors. In
contrast to Woerner et al,15 PTHL3 and HPDMPK were
found to be polymorphic and U79260 could not be ana-
lyzed. Even so, PTHL3 and HPDMPK can be used for MSI
analysis if corresponding normal tissue is available. Fi-
nally, it should be noted that the monomorphic state of
SEC63 and CAT25 was investigated in a limited number
of European (ie, Belgian and Polish) individuals. Use of
this panel in populations of other ethnic origin would
require confirmation of the monomorphic nature in that
population under study.
Distinction between MSI-H and MSS tumors is unam-
biguous when SEC63 and CAT25 are used in conjunction
with BAT26 and BAT25. This MSI analysis is based on the
classification of allelic size variation in more than or equal
to two of four markers as MSI-H and no variation in any
marker as MSS. Although most panels consist of five
markers, this tetraplex assay scored instability in at least
three of four markers in MSI-H samples, suggesting that
the use of a tetraplex mononucleotide panel is suffi-
cient to detect MSI in CRC correctly. It seems to be
unlikely that solely one mononucleotide marker of this
panel would be unstable. Multiplex PCR of these mono-
nucleotide markers has the additional advantage of
Table 2. Comparison of MSI Analysis by Bethesda Panel
and Quasi-Monomorphic Mononucleotide Panel if
MSS and MSI-L Are Combined
Mononucleotide panel
Bethesda panel
MSI-H MSI-L/MSS
MSI-H 29 0
MSI-L/MSS 1 143
Kappa: 0.980 (95CI: 0.940–1.019).
Figure 1. Examples of MSS (A) and MSI-H (B and C) profiles generated with
the quasi-monomorphic mononucleotide multiplex PCR assay. B: Example of
MSI-H where all markers are instable. C: Example of MSI-H where three of
four markers are instable.
New MSI Multiplex Assay in CRC Patients 157
JMD March 2008, Vol. 10, No. 2
avoiding the need for simultaneous analysis of corre-
sponding normal DNA. Since the monomorphic nature
of these new mononucleotides is not known for all
ethnicities, we advise testing the corresponding nor-
mal sample in retrospect when the tumor demonstrates
MSI to confirm that the change was somatically ac-
quired. Moreover, because the reaction is performed in
a single PCR, the method is simple to use and free of
errors arising from the mixing of samples. For all but
one MSI-H case, the Bethesda panel assay demon-
strated instability at both mononucleotide loci (BAT26
and BAT25), the one remaining MSI-H case was insta-
ble in two of three dinucleotide markers (D2S123 and
D17S250).
Using the mononucleotide panel, 29 of 30 tumors pre-
viously classified as MSI-H showed deletions in at least
three of four mononucleotide markers and all cases were
indicative without the analysis of corresponding normal
tissue. The shifts for all mononucleotide loci in the MSI-H
cases resulted in products that were smaller in size than
the germline allele, which is consistent with data of others
demonstrating that deletions in poly(A) sequences are
much more common than insertions.6,23,24 The one
MSI-H case solely instable in two of the dinucleotide
markers of the Bethesda panel showed stability in all four
mononucleotide markers. This strongly suggests the
sample may represent a MSS tumor misclassified by the
dinucleotide markers of the Bethesda panel, a phenom-
enon that has been described previously.8,9,25 However,
immunohistochemistry for MHL1, MSH2, and MSH6
showed loss of expression of MSH2 for this discordant
case. To be absolutely certain, gene sequencing should
be performed for this mismatch repair gene. Unfortu-
nately, due to the formalin-fixed, paraffin-embedded ori-
gin of the sample, which resulted in DNA fragmentation,
it was impossible to perform sequencing analysis.
All of the cases interpreted as MSI-L by the Bethesda
panel assay were scored as MSS by the new mononu-
cleotide panel. Interestingly, all of these shifts were to a
larger allele size, which is less common in MSI-H cases
(Figure 2), and again two of three MSI-L cases showed
evidence of instability in D2S123 locus. These findings
are consistent with those of Murphy et al.6 Furthermore,
D2S123 and D17S250 were found to have the lowest
specificity for MSI analysis when compared to 24 other
microsatellite loci by Bacher et al.10 The findings that all
MSI-L cases resulted from shifts of increasing size in a
single dinucleotide marker without instability in either of
the mononucleotide markers is consistent with the theory
that MSI-H and MSI-L cancers result from distinct
processes.6
Additionally, immunohistochemistry for MHL1, MSH2,
and MSH6 could be performed in two of four MSI-L
cases. One case showed expression of all mismatch
repair proteins indicating microsatellite stability, while the
second sample showed loss of MSH6 protein, which is
described to play a possible role in MSI-L tumors.26
However, the MSI-L phenomenon is poorly defined and
its significance is not well understood, so controversy
remains.27 There is also evidence to suggest that all CRC
have some inherent instability and, if enough markers are
tested, all tumors will have some degree of instability.28 It
has therefore been suggested that MSI-L cancer should
be included with MSS cancers for clinical purposes.8
Thus grouping MSS and MSI-L tumors together, the
agreement between the Bethesda assay and the mono-
nucleotide multiplex assay reached 99.4%. Keeping in
mind that the one MSI-H sample missed by the mononu-
cleotide multiplex assay might have been misclassified
by the dinucleotide markers of the Bethesda panel, this
alternative simple and straightforward MSI analysis sys-
tem of mononucleotide microsatellite repeats can identify
MSI-H tumors with a high sensitivity and specificity. It also
offers several distinct advantages in that it has high ac-
curacy, reliability, and throughput and no need to com-
pare tumor with matching germline DNA. Therefore, it
reduces time and costs involved in MSI testing. Currently,
we are using this multiplex PCR to identify MSI in a large
cohort of colorectal cancer patients to elucidate the clin-
ical and molecular correlation with MSI in CRC.
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